,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny breast04', 'breast']
amid the adulation over destiny breast04, were and i the only people to notice the difference between the #asco22 abstract and the nejm paper? 
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.